These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 12931121

  • 1. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
    Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A, Amylon M, Sullivan KM, Storb RF, Walters MC.
    Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
    [Abstract] [Full Text] [Related]

  • 2. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
    Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC.
    Bone Marrow Transplant; 2005 Jan; 35(2):171-7. PubMed ID: 15531901
    [Abstract] [Full Text] [Related]

  • 3. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [Abstract] [Full Text] [Related]

  • 4. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF.
    JAMA; 2014 Jul 02; 312(1):48-56. PubMed ID: 25058217
    [Abstract] [Full Text] [Related]

  • 5. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS, Agarwal R, Weinberg KI, Wagner JE.
    Biol Blood Marrow Transplant; 2014 Apr 02; 20(4):581-6. PubMed ID: 24370862
    [Abstract] [Full Text] [Related]

  • 6. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.
    Biol Blood Marrow Transplant; 2000 Apr 02; 6(3A):309-20. PubMed ID: 10905768
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 02; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 11. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I, Rowe JM, Khalil A, Ben-Arush M, Elhasid R.
    Biol Blood Marrow Transplant; 2016 Jun 02; 22(6):1043-1048. PubMed ID: 27016193
    [Abstract] [Full Text] [Related]

  • 12. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul 02; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
    Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R.
    Blood; 2003 Sep 15; 102(6):2021-30. PubMed ID: 12791654
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.
    Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR, Roberts IA, Yeager AM, Hsu L, Adamkiewicz T, Kurtzberg J, Vichinsky E, Storer B, Storb R, Sullivan KM, Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease.
    Biol Blood Marrow Transplant; 2001 Sep 15; 7(12):665-73. PubMed ID: 11787529
    [Abstract] [Full Text] [Related]

  • 20. Good engraftment after reduced intensity targeted busulfan-based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies.
    Klink M, Felber M, Zeilhofer U, Hauri-Hohl M, Schmugge M, Drozdov D, Güngör T.
    Pediatr Blood Cancer; 2024 Jul 15; 71(7):e30988. PubMed ID: 38613166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.